ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
12 09 2022
12 09 2022
Historique:
pubmed:
3
9
2022
medline:
16
9
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
In stage II colorectal cancer, adjuvant chemotherapy is controversial, and overtreatment is substantial due to suboptimal risk stratification. In a recent New England Journal of Medicine article reporting from a prospective randomized phase II trial, Tie and colleagues demonstrate how ctDNA-guided risk-stratification reduces the use of adjuvant chemotherapy without compromising recurrence risk.
Identifiants
pubmed: 36055230
pii: S1535-6108(22)00381-6
doi: 10.1016/j.ccell.2022.08.017
pii:
doi:
Substances chimiques
Circulating Tumor DNA
0
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-913Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests C.L.A. declares research funding from C2i Genomics, Delfi Diagnostics, and Natera Inc. E.H. has an unrelated sponsored research agreement with Servier and received funding from Freenome, PreAnalytiX, Illumina, and Roche and honoraria for advisory boards from Roche.